A new vaccine test has been developed that can help doctors confirm a patient’s viral load before administering the vaccine, the Vaccine Safety Datalink reported.
The test is part of the company’s efforts to improve accuracy of the COVID vaccine by providing more accurate doses of vaccine.
A study on the test published in the journal Clinical Infectious Diseases and the US Food and Drug Administration (FDA) said that the vaccine’s ability to detect the virus in the saliva of the infected person has been “significantly improved” over the past four years.
The company said that, for the past two years, a team of experts has tested saliva samples taken from a patient in a clinical trial of the vaccine at several sites in the United States.
Dr Harsh Kumar, senior director of vaccine quality and safety, said that his team has used the saliva test to test the vaccine against the virus since April and has found “no significant differences in the ability of the test to detect COVID from saliva.”
He said that since the test is “not a true nasal swab test,” the results should not be used as a definitive test for viral transmission.
The new test, which uses an infrared spectrometer, was developed by Vaccine Technologies, Inc. (VTE) and the company is currently testing the test at a lab in the UK.VTE is also testing a vaccine called the VXV-CM vaccine, which is similar to the COV-2 vaccine.
According to VTE, the test uses a chemical that is different from the virus that causes COVID and, as such, is less accurate.
The FDA has said that VTE’s new test is not the only vaccine test that can detect COVI-19.
Dr K.M. Raghavendra Rao, who led the study, said the results were “extremely encouraging” and said that he hopes the test will help the FDA “continue to improve its COVID detection capabilities.”
He added that there are currently no clinical trials testing COVID vaccines against COVID.